ArticleFrontiers in immunology2026
Restoration of melatonin rhythms reduces tumour-promoting inflammation in oesophageal cancer survivors: a prospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Blunted nocturnal melatonin amplitude is linked to tumour-promoting inflammation in oesophageal-cancer survivors, but it is unclear whether restoring endogenous rhythms improves clinical outcomes. Methods: In an 18-month prospective cohort conducted in Class 3A hospitals in China and the China Urban Cancer Early Diagnosis and Treatment Project Cohort, 492 stage I-III oesophageal-cancer survivors underwent salivary melatonin profiling and measurement of hs-CRP, IL-6, TNF-α and the neutrophil-to-lymphocyte ratio. Survivors with a night-to-day melatonin ratio < 2.5 initiated a behavioural circadian-realignment programme; rhythm-intact peers received usual care. Linear mixed-effects and Cox models related rhythm restoration to change in composite inflammation burden-calculated as the standardised mean of the four markers-and to major adverse events, adjusting for demographic and clinical covariates. Results: Of 266 rhythm-blunted survivors, 202 (76%) achieved amplitude ≥ 2.5 by 12 months. Their composite inflammation score fell by -0.30 ± 0.18 versus -0.03 ± 0.15 in observation participants (between-group difference -0.27, 95% CI -0.30 to -0.24). Significant time × group interactions were seen for every marker (all p < 0.001). Over 18 months, circadian restoration was associated with a 62% lower hazard of recurrence, cardiovascular events, second primaries or death (adjusted HR 0.38, 95% CI 0.21-0.68). Pittsburgh Sleep Quality Index improved by -2.7 points relative to usual care. Conclusion: Behavioural realignment of endogenous melatonin rhythms was associated with sustained reductions in systemic inflammation and fewer adverse events in oesophageal-cancer survivors. Routine circadian-hygiene counselling combined with simple salivary monitoring may help support long-term oncologic and cardiometabolic health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.